SABCS

Losing even a moderate amount of extra weight significantly reduces the risk of breast cancer for postmenopausal women, a researcher reports.

The incidence of human papillomavirus-related oropharyngeal cancer (HPV-OPC) is on the rise. Researchers at Johns Hopkins University assessed survey data to determine whether the risk among the general population is rising as well. Results show that for most people, the risk remains low.

Talazoparib, a PARP inhibitor is more effective than chemotherapy in reducing the risk of disease progression and death from BRCA-positive breast cancer.

Researchers find that women with postmenopausal hormone receptor (HR)-positive breast cancer may undergo shorter treatments of Arimidex, which may in turn cause less bone fractures.

A phase 3 clinical trial pitted a nine-week treatment of adjuvant Herceptin against the regimen of a full year of treatment for patients with HER2-positive breast cancer. Results show that the standard treatment of one year is still optimal.

To address compliance issues associated with treatment using aromatase inhibitors, researchers show that acupuncture effectively eases joint pain, a side effect from hormone therapy.

A reveiw of five clinical trial findings suggests that gonadotropin-releasing hormone analog has the potential to preserve ovarian function and fertility in premenopausal breast cancer patients.

New research demonstrates that a CDK4/6 inhibitor, used in combination with standard endocrine therapy with temporary ovarian suppression significantly improves progression-free survival in younger patients who currently have few treatment options.

The combination of Keytruda (pembrolizumab) and Herceptin (trastuzumab) showed promise for the treatment of women with Herceptin-resistant, PD-L1–positive, HER2-positive breast cancer.

A stud presented at SABCS shows that IMMU-132, an antibody-drug conjugate, improves outcomes in women with heavily pretreated metastatic triple-negative breast cancer.

The combination use of Herceptin plus standard adjuvant chemotherapy does not improve outcomes in women with HER2-low breast cancer.

For women with early-stage breast cancer who are receiving chemotherapy, shortening the time between treatment cycles or administering the agents sequentially may reduce disease recurrence and mortality compared with standard chemotherapy regimens.